专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160287605A1 COMBINATION THERAPY 审中-公开
标题翻译：组合治疗
公开(公告)号：US20160287605A1
公开(公告)日：2016-10-06
申请号：US15184399
申请日：2016-06-16
申请人： Qing Sheng , Hui-Qin Wang , Fang Li , Jinsheng Liang , Zhu Alexander Cao , John Monahan , Richard Versace
发明人： Qing Sheng , Hui-Qin Wang , Fang Li , Jinsheng Liang , Zhu Alexander Cao , John Monahan , Richard Versace
IPC分类号： A61K31/5377 , A61K31/506
CPC分类号： A61K31/5355 , A61K31/365 , A61K31/395 , A61K31/416 , A61K31/506 , A61K31/519 , A61K31/52 , A61K31/5377 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical combination comprising (a) a compound of formula (I), or pharmaceutically acceptable salts thereof; and (b) one or more at least one compound targeting, decreasing or inhibiting the intrinsic ATPase activity of Hsp90 and/or degrading, targeting, decreasing or inhibiting the Hsp90 client proteins via the ubiquitin proteosome pathway; the uses of such combination in the treatment or prevention of proliferative diseases; and methods of treating a subject suffering.
摘要翻译：或其药学上可接受的盐; 和（b）一种或多种至少一种靶向，降低或抑制Hsp90的内在ATP酶活性和/或通过泛素蛋白酶途径降解，靶向，降低或抑制Hsp90客体蛋白的化合物; 这种组合在治疗或预防增殖性疾病中的用途; 以及治疗受试者的方法。

2. 发明申请

US20160339023A1 Pharmaceutical Combinations 审中-公开
标题翻译：药物组合
公开(公告)号：US20160339023A1
公开(公告)日：2016-11-24
申请号：US15107232
申请日：2014-12-19
申请人： Fang Li , Hui-Qin WANG , Ensar HALILOVIC , Jinsheng LIANG
发明人： Fang Li , Hui-Qin WANG , Ensar HALILOVIC , Jinsheng LIANG
IPC分类号： A61K31/506 , A61K31/496
CPC分类号： A61K31/506 , A61K31/4025 , A61K31/404 , A61K31/435 , A61K31/496 , A61K45/06 , A61K2300/00
摘要： A pharmaceutical combination comprising (a) an ALK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) at least one HDMA-2/p53 receptor inhibitor or a pharmaceutically acceptable salt, or at least one BRaf inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration; the uses of such combination in the treatment of cancer; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
摘要翻译：一种药物组合，其包含（a）ALK抑制剂或其药学上可接受的盐，和（b）至少一种HDMA-2 / p53受体抑制剂或其药学上可接受的盐，或至少一种BRaf抑制剂或药学上可接受的盐，和任选的药学上可接受的载体，用于同时，分别或连续施用; 这种组合在治疗癌症中的用途; 以及治疗患有增殖性疾病的受试者的方法，包括施用治疗有效量的这种组合。

3. 发明申请

US20160331751A1 PHARMACEUTICAL COMPOSITIONS 审中-公开
标题翻译：药物组合物
公开(公告)号：US20160331751A1
公开(公告)日：2016-11-17
申请号：US15106886
申请日：2014-12-19
申请人： Stephane Ferretti , Sebastien Jeay , Ensar Halilovic , Fang Li , Hui-Qin Wang
发明人： Stephane Ferretti , Sebastien Jeay , Ensar Halilovic , Fang Li , Hui-Qin Wang
IPC分类号： A61K31/519 , A61K31/506 , A61K31/496
CPC分类号： A61K31/519 , A61K31/4188 , A61K31/496 , A61K31/505 , A61K31/506 , A61K2300/00
摘要： The disclosure relates to a pharmaceutical combination of a mdm2/4 inhibitor, namely (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one or (S)-5-(5-Chloro-1-methyl-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-2-(2,4-dimethoxy-pyrimidin-5-yl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-d]imidazol-4-one, and a cyclin dependent kinase 4/6 (CDK4/6) inhibitor 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide. In addition, the disclosure relates to a pharmaceutical combination product. The disclosure also relates to corresponding pharmaceutical formulations, uses and treatment methods comprising said mdm2/4 inhibitor or a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.
摘要翻译：本公开涉及mdm2 / 4抑制剂的药物组合，即（S）-1-（4-氯 - 苯基）-7-异丙氧基-6-甲氧基-2-（4- {甲基 - [4-（4 - 甲基-3-氧代 - 哌嗪-1-基） - 反式 - 环己基甲基] - 氨基} - 苯基）-1,4-二氢-2H-异喹啉-3-酮或（S）-5-（5-氯 - -1-甲基-2-氧代-1,2-二氢 - 吡啶-3-基）-6-（4-氯 - 苯基）-2-（2,4-二甲氧基 - 嘧啶-5-基）-1-异丙基 -5,6-二氢-1H-吡咯并[3,4-d]咪唑-4-酮和细胞周期蛋白依赖性激酶4/6（CDK4 / 6）抑制剂7-环戊基-2-（5-哌嗪-1-基）吡啶-2-基氨基）-7H-吡咯并[2,3-d]嘧啶-6-甲酸二甲基酰胺。此外，本公开涉及药物组合产品。本公开还涉及包含所述mdm2 / 4抑制剂或细胞周期蛋白依赖性激酶4/6（CDK4 / 6）抑制剂的相应药物制剂，用途和治疗方法。

4. 发明申请

US20170252335A1 Combination of Ceritinib with an EGFR Inhibitor 审中-公开
公开(公告)号：US20170252335A1
公开(公告)日：2017-09-07
申请号：US15519593
申请日：2015-10-15
申请人： Serafino Pantano , Fang Li , Nanxin Li , Anthony Boral
发明人： Serafino Pantano , Fang Li , Nanxin Li , Anthony Boral
IPC分类号： A61K31/4706 , A61K31/4709 , A61K31/506 , C07K16/32 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K39/395 , A61K31/517
CPC分类号： A61K31/4706 , A61K31/4709 , A61K31/506 , A61K31/517 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K39/395 , A61K39/39558 , A61K45/06 , A61K2300/00 , C07K16/32
摘要： The present disclosure relates to a pharmaceutical composition comprising two Tyrosine Kinase Inhibitors (TKIs), namely Ceritinib and an EGFR Inhibitor. The present combination can be administered independently or separately, in a quantity which is jointly therapeutically effective for the treatment of a TKI mediated disease, such as cancer. The disclosure also provides the use of such a combination for the manufacture of a medicament; the use of such a combination as a medicine; a kit of part comprising such a combination; and a method of treatment of such a combination.

5. 发明授权

US09217118B2 Polyalkylene glycol-grafted polycarboxylate suspension and dispersing agent for cutting fluids and slurries 有权
标题翻译：聚亚烷基二醇接枝聚羧酸盐悬浮液和分散剂，用于切削液体和浆料
公开(公告)号：US09217118B2
公开(公告)日：2015-12-22
申请号：US13500572
申请日：2009-10-16
申请人： Linda Yi-Ping Zhu , Wanglin Yu , Fang Li , Daniel A. Aguilar , David B. Wurm
发明人： Linda Yi-Ping Zhu , Wanglin Yu , Fang Li , Daniel A. Aguilar , David B. Wurm
IPC分类号： B26D1/547 , C08K5/06 , C10M169/04 , C10M173/02
CPC分类号： C10M111/04 , B24B27/0633 , B28D5/045 , C10M169/044 , C10M173/02 , C10M2201/02 , C10M2201/061 , C10M2201/10 , C10M2209/084 , C10M2209/086 , C10M2209/1045 , C10N2230/02 , C10N2230/04 , C10N2240/401 , C10M2209/104 , C10M2209/109
摘要： Cutting fluids for brittle materials, e.g., silicon ingot, comprise, in weight percent: A. 70-99% polyalkylene glycol (PAG), e.g., polyethylene glycol; B. 0.01-10% PAG-grafted polycarboxylate; and C. 0-30% water. These cutting fluids are used with abrasive materials, e.g., silicon carbide (SiC), to form cutting slurries. The slurry is sprayed on the cutting tool, e.g., a wire saw, to cut a brittle work piece, e.g., a silicon ingot.
摘要翻译：用于脆性材料例如硅锭的切削液包含重量百分比：A.70-99％的聚亚烷基二醇（PAG），例如聚乙二醇; B. 0.01-10％PAG接枝的聚羧酸酯; 和0-30％的水。这些切削液与研磨材料（例如碳化硅（SiC））一起使用以形成切割浆料。将浆料喷涂在切割工具，例如线锯上，以切割脆性工件，例如硅锭。

6. 发明申请

US20150190456A1 USE OF CASPASE 3 ACTIVITY AND ITS INHIBITORS 审中-公开
标题翻译：使用CASPASE 3活性及其抑制剂
公开(公告)号：US20150190456A1
公开(公告)日：2015-07-09
申请号：US14128228
申请日：2012-06-20
申请人： Chuan-Yuan Li , Qian Huang , Fang Li
发明人： Chuan-Yuan Li , Qian Huang , Fang Li
IPC分类号： A61K38/00 , G01N33/574 , A61K31/5377 , A61K31/27 , A61K45/06 , A61K31/404
CPC分类号： A61K38/005 , A61K31/10 , A61K31/27 , A61K31/404 , A61K31/5377 , A61K45/06 , G01N33/57407 , G01N33/57415 , G01N33/57419 , G01N33/5743 , G01N2333/96466 , G01N2800/54
摘要： The present invention provides methods for using the level of caspase 3 activity for determining or prognosticating likelihood of cancer recurrence or relapse in a patient after the treatment for cancer. The present invention also provides methods for treating cancer in a patient using a caspase 3 inhibitor in conjunction with a conventional cancer treatment.
摘要翻译：本发明提供使用胱天蛋白酶3活性水平来确定或预测癌症治疗后患者癌症复发或复发的可能性的方法。本发明还提供了结合常规癌症治疗使用胱天蛋白酶3抑制剂治疗患者癌症的方法。

7. 发明申请

US20120314202A1 POLARISCOPE STRESS MEASUREMENT TOOL AND METHOD OF USE 失效
标题翻译：极化应力测量工具及其使用方法
公开(公告)号：US20120314202A1
公开(公告)日：2012-12-13
申请号：US13571481
申请日：2012-08-10
申请人： Steven Danyluk , Fang Li
发明人： Steven Danyluk , Fang Li
IPC分类号： G01B11/16 , G01J4/00
CPC分类号： G01B11/168 , G01L1/241 , G01L5/0047
摘要： The present invention provides a tool for and method of using an infrared transmission technique to extract the full stress components of the in-plane residual stresses in thin, multi crystalline silicon wafers including in situ measurement of residual stress for large cast wafers. The shear difference method is used to obtain full stress components by integrating the shear stress map from the boundaries. System ambiguity at the boundaries is resolved completely by introducing a new analytical function. A new anisotropic stress optic law is provided, and stress optic coefficients are calibrated for different crystal grain orientations and stress orientations.
摘要翻译：本发明提供了一种使用红外透射技术提取薄多晶硅晶片中的平面内残余应力的全应力分量的工具和方法，包括原位测量大型晶圆的残余应力。剪切差法用于通过从边界积分剪切应力图来获得全应力分量。通过引入新的分析功能，完全解决了边界的系统模糊。提供了新的各向异性应力光学定律，并且针对不同的晶粒取向和应力取向校准了应力光学系数。

8. 发明授权

US07741434B2 High-affinity antagonists of ELR-CXC chemokines 有权
标题翻译： ELR-CXC趋化因子的高亲和力拮抗剂
公开(公告)号：US07741434B2
公开(公告)日：2010-06-22
申请号：US12172333
申请日：2008-07-14
申请人： John R. Gordon , Fang Li
发明人： John R. Gordon , Fang Li
IPC分类号： C07K14/52
CPC分类号： C07K14/5421
摘要： The present invention provides novel polypeptide sequences, methods for production thereof and uses thereof for novel ELR-CXC chemokine receptor agonists and antagonists.
摘要翻译：本发明提供新的多肽序列，其制备方法及其用于新型ELR-CXC趋化因子受体激动剂和拮抗剂的用途。

9. 发明申请

US20070021593A1 High-affinity antagonists of ELR-CXC chemokines 审中-公开
标题翻译： ELR-CXC趋化因子的高亲和力拮抗剂
公开(公告)号：US20070021593A1
公开(公告)日：2007-01-25
申请号：US11434155
申请日：2006-05-16
申请人： John Gordon , Fang Li
发明人： John Gordon , Fang Li
IPC分类号： A61K38/19 , C07K14/52
CPC分类号： C07K14/5421
摘要： The present invention provides novel polypeptide sequences, methods for production thereof and uses thereof for novel ELR—CXC chemokine receptor agonists and antagonists.
摘要翻译：本发明提供新的多肽序列，其制备方法及其用于新型ELR-CXC趋化因子受体激动剂和拮抗剂的用途。

10. 发明授权

US08898027B2 Method and system for a comprehensive analysis of low frequency oscillation 有权
标题翻译：低频振荡综合分析方法与系统
公开(公告)号：US08898027B2
公开(公告)日：2014-11-25
申请号：US12996896
申请日：2009-09-04
申请人： Yaozhong Xin , Fang Li , Jingtao Wu , Hongzhu Tao , Jianfeng Yan , Gang Duan , Fang Tian , Yu Dong , Wei Zhang
发明人： Yaozhong Xin , Fang Li , Jingtao Wu , Hongzhu Tao , Jianfeng Yan , Gang Duan , Fang Tian , Yu Dong , Wei Zhang
IPC分类号： G01R23/00 , H02J3/24
CPC分类号： H02J3/24
摘要： A method and a system for a comprehensive analysis of low frequency oscillation. The method includes: firstly, initiating a wide area measurement system WAMS (71) to perform real-time monitoring; transmitting real-time low frequency oscillation information to a dynamic early-warning system (72) periodically; then converting the low frequency oscillation information received by the dynamic early-warning system (72) into an input file for stability calculation with small disturbance, and performing related calculation; finally, transmitting the calculated result back to the wide area measurement system WAMS (71) and a human-machine system interface for output. The system includes: the wide area measurement system WAMS (71), the dynamic early-warning system (72), a system for stability calculation with small disturbance (73) and an output system (74).
摘要翻译：一种综合分析低频振荡的方法和系统。该方法包括：首先启动广域测量系统WAMS（71）进行实时监控; 周期性地将实时低频振荡信息发送到动态预警系统（72）; 然后将由动态预警系统（72）接收的低频振荡信息转换成具有小干扰的用于稳定性计算的输入文件，并执行相关计算; 最后，将计算结果传送回广域测量系统WAMS（71）和人机界面进行输出。该系统包括：广域测量系统WAMS（71），动态预警系统（72），小干扰稳定计算系统（73）和输出系统（74）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式